Comparative analysis of triplex nucleic acid test assays in United States blood donors
Version of Record online: 3 APR 2013
© 2013 American Association of Blood Banks
Special Issue: Thirty Years of Progress since Recognition of Transfusion-Associated AIDS
Volume 53, Issue 10pt2, pages 2525–2537, October 2013
How to Cite
Stramer, S. L., Krysztof, D. E., Brodsky, J. P., Fickett, T. A., Reynolds, B., Dodd, R. Y. and Kleinman, S. H. (2013), Comparative analysis of triplex nucleic acid test assays in United States blood donors. Transfusion, 53: 2525–2537. doi: 10.1111/trf.12178
- Issue online: 4 OCT 2013
- Version of Record online: 3 APR 2013
- Manuscript Accepted: 13 FEB 2013
- Manuscript Revised: 6 FEB 2013
- Manuscript Received: 17 DEC 2012
- 1Roche Molecular Systems, Inc. cobas® TaqScreen MPX Test for use on the cobas s 201 System product insert: 1636, Rev4. 2009. Indianapolis, IN, USA.
- 2Gen-Probe, Incorporated. Procleix® Ultrio® Assay product insert: 502165, Rev. A. 2011. San Diego, CA, USA.
- 3Gen-Probe, Incorporated. Procleix® Ultrio® Plus Assay product insert: 502932, Rev. 7. 2012. San Diego, CA, USA.
- 5Sensitivity of two hepatitis B virus, hepatitis C virus (HCV), and human immunodeficiency virus (HIV) nucleic acid test systems relative to hepatitis B surface antigen, anti-HCV, anti-HIV, and p24/anti-HIV combination assays in seroconversion panels. Transfusion 2009;49:301-310., , , , , , , , , .
- 7The Working Group for NAT Study in Thai Blood Donations. One-year experience of nucleic acid technology testing for human immunodeficiency virus type 1, hepatitis C virus, and hepatitis B virus in Thai blood donations. Transfusion 2009;49:1126-1135., , , , , , , , , , , ;
- 9Sensitivity comparison of two Food and Drug Administration–licensed, triplex nucleic acid test automated assays for hepatitis B virus DNA detection and associated projections of United States yield. Transfusion 2011;51:2012-2022., , , , , , , , , .
- 17US Food and Drug Administration. Guidance for industry: nucleic acid testing (NAT) for human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV): testing, product disposition, and donor deferral and reentry. May 2010 [cited 2012 Dec 2]. Available from: URL: http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm
- 18US Food and Drug Administration. Guidance for industry: use of nucleic acid tests on pooled and individual samples from donors of whole blood and blood components, including source plasma, to reduce the risk of transmission of hepatitis B virus. Oct 2012. [cited 2012 Dec 2]. Available from: URL: http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm
- 20the National Heart, Lung, and Blood Institute Nucleic Acid Test Study Group. Relative sensitivities of licensed nucleic acid amplification tests for detection of viremia in early human immunodeficiency virus and hepatitis C virus infection. Transfusion 2005;45:1853-1863., , , , , , , , , , for
- 28Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa. Transfusion 2009;49:1115-1125., , , , , , , , , .
- 31Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion 2010;50:1495-1504., , , , , , , .
- 32Integration of nucleic acid amplification test results into hepatitis C virus supplemental serologic testing algorithms: implications for donor counseling and revision of existing algorithms. Transfusion 2006;46:695-702., , , , .